Twin Capital Management Inc. Has $7.50 Million Stock Position in AbbVie Inc. $ABBV

Twin Capital Management Inc. lifted its position in shares of AbbVie Inc. (NYSE:ABBV) by 3.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 40,405 shares of the company’s stock after buying an additional 1,359 shares during the quarter. AbbVie comprises about 0.8% of Twin Capital Management Inc.’s holdings, making the stock its 22nd largest position. Twin Capital Management Inc.’s holdings in AbbVie were worth $7,500,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Marshall & Sullivan Inc. WA bought a new stake in AbbVie during the second quarter worth $25,000. TD Capital Management LLC grew its stake in shares of AbbVie by 82.9% in the 1st quarter. TD Capital Management LLC now owns 128 shares of the company’s stock worth $27,000 after acquiring an additional 58 shares in the last quarter. Spurstone Advisory Services LLC purchased a new stake in shares of AbbVie in the second quarter valued at about $28,000. Cypress Capital Management LLC WY purchased a new position in AbbVie during the first quarter worth about $35,000. Finally, Bear Mountain Capital Inc. grew its position in AbbVie by 480.6% in the 2nd quarter. Bear Mountain Capital Inc. now owns 209 shares of the company’s stock worth $40,000 after purchasing an additional 173 shares in the last quarter. 70.23% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on ABBV. Daiwa America upgraded shares of AbbVie from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 7th. HSBC set a $225.00 target price on AbbVie in a report on Thursday, October 2nd. UBS Group set a $251.00 price objective on AbbVie in a report on Friday, October 3rd. Guggenheim boosted their target price on shares of AbbVie from $227.00 to $242.00 and gave the company a “buy” rating in a report on Monday, October 20th. Finally, Wall Street Zen upgraded shares of AbbVie from a “hold” rating to a “buy” rating in a report on Saturday, October 25th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $238.05.

Insiders Place Their Bets

In other news, EVP Azita Saleki-Gerhardt sold 42,370 shares of the stock in a transaction that occurred on Tuesday, August 12th. The stock was sold at an average price of $198.42, for a total value of $8,407,055.40. Following the sale, the executive vice president directly owned 177,292 shares in the company, valued at approximately $35,178,278.64. This represents a 19.29% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.25% of the stock is owned by company insiders.

AbbVie Price Performance

ABBV opened at $216.96 on Thursday. The stock has a market capitalization of $383.27 billion, a P/E ratio of 103.31, a P/E/G ratio of 1.42 and a beta of 0.50. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.61 and a current ratio of 0.74. The company’s 50-day simple moving average is $222.84 and its two-hundred day simple moving average is $201.84. AbbVie Inc. has a 52-week low of $163.81 and a 52-week high of $244.81.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping the consensus estimate of $1.77 by $0.09. The company had revenue of $15.78 billion during the quarter, compared to analyst estimates of $15.58 billion. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.AbbVie’s revenue was up 9.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.00 earnings per share. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, analysts predict that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be paid a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, January 16th. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 annualized dividend and a yield of 3.2%. AbbVie’s payout ratio is presently 524.24%.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.